-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25

Benzinga·08/06/2026 11:12:05
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Buy rating and announces Price Target of $25.